SURGEPAYS INC (SURG) Stock Fundamental Analysis

NASDAQ:SURG • US86882L2043

0.9 USD
-0.03 (-3.42%)
Last: Feb 27, 2026, 10:17 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall SURG gets a fundamental rating of 2 out of 10. We evaluated SURG against 22 industry peers in the Wireless Telecommunication Services industry. SURG may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SURG is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SURG had negative earnings in the past year.
  • In the past year SURG has reported a negative cash flow from operations.
  • In the past 5 years SURG reported 4 times negative net income.
  • In multiple years SURG reported negative operating cash flow during the last 5 years.
SURG Yearly Net Income VS EBIT VS OCF VS FCFSURG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • SURG has a Return On Assets of -289.89%. This is amonst the worse of the industry: SURG underperforms 95.45% of its industry peers.
Industry RankSector Rank
ROA -289.89%
ROE N/A
ROIC N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURG Yearly ROA, ROE, ROICSURG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SURG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURG Yearly Profit, Operating, Gross MarginsSURG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SURG has more shares outstanding
  • The number of shares outstanding for SURG has been increased compared to 5 years ago.
  • SURG has a worse debt/assets ratio than last year.
SURG Yearly Shares OutstandingSURG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
SURG Yearly Total Debt VS Total AssetsSURG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -13.67, we must say that SURG is in the distress zone and has some risk of bankruptcy.
  • SURG has a Altman-Z score of -13.67. This is amonst the worse of the industry: SURG underperforms 86.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.67
ROIC/WACCN/A
WACC8.6%
SURG Yearly LT Debt VS Equity VS FCFSURG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • SURG has a Current Ratio of 0.52. This is a bad value and indicates that SURG is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.52, SURG is doing worse than 90.91% of the companies in the same industry.
  • A Quick Ratio of 0.41 indicates that SURG may have some problems paying its short term obligations.
  • SURG has a worse Quick ratio (0.41) than 90.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.41
SURG Yearly Current Assets VS Current LiabilitesSURG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for SURG have decreased strongly by -87.61% in the last year.
  • The Revenue for SURG has decreased by -39.75% in the past year. This is quite bad
  • The Revenue has been growing by 18.83% on average over the past years. This is quite good.
EPS 1Y (TTM)-87.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.32%
Revenue 1Y (TTM)-39.75%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%291.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 42.27% on average over the next years. This is a very strong growth
  • SURG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 49.06% yearly.
EPS Next Y44.42%
EPS Next 2Y42.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.09%
Revenue Next 2Y49.06%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SURG Yearly Revenue VS EstimatesSURG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M
SURG Yearly EPS VS EstimatesSURG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • SURG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 16.04, SURG is valued correctly.
  • SURG's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. SURG is more expensive than 63.64% of the companies in the same industry.
  • SURG's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.13.
Industry RankSector Rank
PE N/A
Fwd PE 16.04
SURG Price Earnings VS Forward Price EarningsSURG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURG Per share dataSURG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • SURG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • SURG's earnings are expected to grow with 42.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.27%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SURG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SURGEPAYS INC

NASDAQ:SURG (2/27/2026, 10:17:45 AM)

0.9

-0.03 (-3.42%)

Chartmill FA Rating
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)11-12
Earnings (Next)03-23
Inst Owners8.28%
Inst Owner Change20.16%
Ins Owners35.07%
Ins Owner Change2.83%
Market Cap21.09M
Revenue(TTM)50.37M
Net Income(TTM)-42.02M
Analysts80
Price Target9.95 (1005.56%)
Short Float %3.95%
Short Ratio2.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-113.07%
Min EPS beat(2)-150.17%
Max EPS beat(2)-75.97%
EPS beat(4)0
Avg EPS beat(4)-147.6%
Min EPS beat(4)-304.04%
Max EPS beat(4)-60.24%
EPS beat(8)0
Avg EPS beat(8)-211.45%
EPS beat(12)4
Avg EPS beat(12)-3.65%
EPS beat(16)4
Avg EPS beat(16)-210.79%
Revenue beat(2)1
Avg Revenue beat(2)-14.47%
Min Revenue beat(2)-30.02%
Max Revenue beat(2)1.08%
Revenue beat(4)2
Avg Revenue beat(4)-7.34%
Min Revenue beat(4)-30.02%
Max Revenue beat(4)14.43%
Revenue beat(8)3
Avg Revenue beat(8)-9.47%
Revenue beat(12)3
Avg Revenue beat(12)-9.6%
Revenue beat(16)5
Avg Revenue beat(16)-8.22%
PT rev (1m)0%
PT rev (3m)2.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-328.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-59.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-32.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 16.04
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)0.06
Fwd EY6.23%
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS2.15
BVpS-0.27
TBVpS-0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -289.89%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover3.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.41
Altman-Z -13.67
F-Score2
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.32%
EPS Next Y44.42%
EPS Next 2Y42.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-39.75%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%291.64%
Revenue Next Year4.09%
Revenue Next 2Y49.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-76.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-300.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-296.08%
OCF growth 3YN/A
OCF growth 5YN/A

SURGEPAYS INC / SURG FAQ

Can you provide the ChartMill fundamental rating for SURGEPAYS INC?

ChartMill assigns a fundamental rating of 2 / 10 to SURG.


Can you provide the valuation status for SURGEPAYS INC?

ChartMill assigns a valuation rating of 3 / 10 to SURGEPAYS INC (SURG). This can be considered as Overvalued.


What is the profitability of SURG stock?

SURGEPAYS INC (SURG) has a profitability rating of 0 / 10.


What is the expected EPS growth for SURGEPAYS INC (SURG) stock?

The Earnings per Share (EPS) of SURGEPAYS INC (SURG) is expected to grow by 44.42% in the next year.